[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transurethral-resection-of-the-prostate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transurethral-resection-of-the-prostate":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100628352","phase-4-tranexamic-acid-for-bleeding-reduction-during-turp-surgery-100628352",false,"NCT07460518","Tranexamic Acid for Bleeding Reduction During TURP Surgery","Tranexamic Acid for Perioperative Haemostatic Optimisation During Transurethral Resection of the Prostate: A Randomized Quadruple-Blind Placebo-Controlled Trial","TXA-TURP","Inclusion Criteria:\n\n* Male patients aged 50 years or older\n* Diagnosed with benign prostatic hyperplasia (BPH)\n* Scheduled for elective transurethral resection of the prostate (TURP) under spinal anesthesia\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Provided written informed consent\n\nExclusion Criteria:\n\n* History of thromboembolic disease (deep vein thrombosis, pulmonary embolism, stroke)\n* Known hypersensitivity to tranexamic acid\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Coagulation disorders\n* Current anticoagulant therapy not appropriately discontinued\n* History of seizure disorder\n* Refusal to participate","MALE","50 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Transurethral resection of the prostate (TURP) is commonly performed in elderly patients and may be associated with perioperative bleeding leading to postoperative anemia and delayed recovery. Tranexamic acid (TXA), an antifibrinolytic agent, may reduce surgical bleeding by inhibiting fibrin degradation.\n\nThis prospective randomized quadruple-blind placebo-controlled clinical trial evaluates whether perioperative administration of intravenous tranexamic acid reduces intraoperative blood loss and preserves postoperative hemoglobin concentration in patients undergoing TURP under standardized spinal anesthesia.\n\nParticipants are randomly assigned to receive either intravenous tranexamic acid or placebo prior to surgery. The primary outcomes assess objective measures of perioperative blood loss and postoperative hemoglobin levels. Secondary outcomes include recovery parameters, perioperative safety, and exploratory hospital-level economic impact.\n\nThe study aims to determine whether anesthesia-led haemostatic optimization using tranexamic acid improves perioperative physiological stability and recovery efficiency within an enhanced recovery framework.",[27,28,29,30],"Benign Prostatic Hyperplasia","Transurethral Resection of the Prostate","Perioperative Bleeding","Anemia, Postoperative",[32,33,34,35,36,37,38,39],"Tranexamic Acid","TURP","Patient Blood Management","Spinal Anesthesia","Randomized Controlled Trial","Hemostasis","Enhanced Recovery After Surgery","Perioperative Medicine","NOT_YET_RECRUITING","2026-03-05",{"date":43,"type":44},"2026-03-10","ACTUAL",{"date":46,"type":21},"2026-03-15",{"date":48,"type":21},"2026-09-01",{"name":50,"class":51},"Hamza Najout","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":52},"100620904","inhalational-agents-versus-dexmedetomidine-for-maintenance-of-general-anesthesia-100620904","NCT07363681","Inhalational Agents Versus Dexmedetomidine for Maintenance of General Anesthesia","Beyond Inhalational Agents: Dexmedetomidine for Maintenance of General Anesthesia - A Prospective Randomized Clinical Trial","Inclusion Criteria\n\n* Age ≥ 39 years\n* Classified as ASA physical status II-IV\n* Scheduled for elective endoscopic urological surgery (e.g., URS, TUR-B, PCNL, TUR-P)\n* Scheduled for postoperative follow-up in the Post-Anesthesia Care Unit (PACU)\n* Ability to provide written informed consent\n\nExclusion Criteria\n\n* Requirement for conversion to open surgery during the perioperative period\n* Patients who decline to participate in the study\n* Presence of neuropsychiatric disorders (e.g., dementia, Parkinson's disease, epilepsy, or history of head trauma)\n* History of alcohol or substance abuse\n* Use of psychoactive medications\n* Inability to communicate adequately for any reason",true,"ALL","39 Years","99 Years",{"count":65,"type":21},150,[67],"NA","The climate crisis and environmental pollution are escalating day by day, making the reduction of carbon footprints increasingly important both on an individual and industrial level. Inhalational anesthetic agents are widely used in daily anesthesia practice. However, some of these agents are released into the environment either unchanged or as metabolic by-products. It can take hundreds of years for these substances to be fully eliminated from nature. Therefore, there is a growing interest in identifying alternative anesthetic agents that are fully metabolized, do not produce waste, have a shorter duration of action, and pose less harm to ecosystems.\n\nRecent clinical studies have shown that dexmedetomidine, when administered intraoperatively via infusion without a loading dose and in combination with inhalational agents, provides more stable hemodynamics and results in a shorter postoperative recovery period. Commonly used as a long-term sedative agent in intensive care units, dexmedetomidine has gained popularity in the intraoperative setting due to its stable hemodynamic profile, low incidence of withdrawal symptoms, and faster recovery.\n\nIn this study, it is aimed to demonstrate the potential use of dexmedetomidine-whose pharmacodynamic and pharmacokinetic properties are well-known to experienced anesthesiologists-as an alternative to inhalational anesthetic agents for the maintenance of anesthesia, particularly in the geriatric patient population.",[70,71,72,28],"Ureterorenoscopic Lithotripsy","Transurethral Resection of the Bladder","Percutaneous Nephrolithotomy","RECRUITING","2026-01-15",{"date":76,"type":44},"2026-01-23",{"date":78,"type":44},"2024-10-01",{"date":80,"type":21},"2026-03-09",{"name":82,"class":83},"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","OTHER_GOV"]